FDA recommended that Compass Therapeutics conduct a survival-benefit trial before submitting a BLA for tovecimig, despite data showing a 56% reduction in disease-progression risk. The feedback matters because the company says it plans further FDA discussions and believes the existing COMPANION-002 results support moving toward a BLA without another trial.
Key Highlights
- FDA recommended a survival-benefit trial before Compass Therapeutics submits a BLA for tovecimig.
- Tovecimig plus paclitaxel produced an 18.0% objective response rate versus 5.3% for paclitaxel alone.
- Compass Therapeutics plans further discussions with FDA as it prepares a potential BLA submission.
Compass Therapeutics, Inc. (NASDAQ: CMPX) is a Pharmaceuticals: Major company. FDA feedback now calls for survival-benefit evidence before a Biologics license application for tovecimig in previously treated, advanced biliary tract cancer. Compass Therapeutics says it does not believe another trial is warranted before a BLA based on existing study results and the urgent medical need in BTC.
FDA Recommendation Adds Survival Evidence Requirement
Tovecimig was evaluated with paclitaxel in the COMPANION-002 study, where objective response rate improved to 18.0% from 5.3% with paclitaxel alone, with a p-value of 0.0228. Median progression-free survival reached 4.7 months versus 2.6 months, while the hazard ratio was 0.44 and the p-value was below 0.0001. Overall-survival analysis was affected by extensive crossover and prolonged survival among patients who moved from the control group to tovecimig, and the result did not reach statistical significance. The treatment’s safety profile was generally consistent with earlier tovecimig studies. Compass intends to continue engaging with FDA while preparing a BLA submission for tovecimig.
FAQs
Q: What did FDA recommend for Compass Therapeutics’ tovecimig BLA?
A: FDA recommended a trial showing a survival benefit before Compass Therapeutics submits a BLA for tovecimig in previously treated, advanced biliary tract cancer.
Q: How did tovecimig perform on progression-free survival?
A: Median progression-free survival was 4.7 months with tovecimig and paclitaxel, compared with 2.6 months for paclitaxel alone. The hazard ratio was 0.44.
Q: What is Compass Therapeutics planning after FDA feedback?
A: Compass intends to continue discussions with FDA while preparing a BLA submission for tovecimig. The company says another trial is not warranted before submission.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.